Moderna in fill-finish agreement with Novocol Pharma for mRNA vaccines
Maddie Meyer

Moderna (NASDAQ:MRNA) and Ontario-based Novocol Pharma have signed an agreement for the latter to provide fill-finish, labelling and packaging of mRNA respiratory vaccines produced in Canada.
The agreement will support Moderna's (MRNA) mRNA vaccine production operations in Laval, Quebec, which are expected to begin by the end of 2024.

Moderna (MRNA) also received a grant from the Government of Ontario to support its production efforts.
The biotech's respiratory syncytial virus (RSV) candidate, mRNA-1345, is in phase 3 of development.

More on Moderna

Moderna to build mRNA vaccine manufacturing facility in Quebec
Moderna's mRNA Revolution: Unveiling A World Of Investment Potential Beyond COVID-19
Moderna Is Great Value For Money Right Now